{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:18:01Z","timestamp":1778253481098,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801094"],"award-info":[{"award-number":["81801094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071177"],"award-info":[{"award-number":["82071177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neuropharm.2021.108703","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T01:16:06Z","timestamp":1625966166000},"page":"108703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Activation of the spinal EGFR signaling pathway in a rat model of cancer-induced bone pain with morphine tolerance"],"prefix":"10.1016","volume":"196","author":[{"given":"Yaqiong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Xiang Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-5593","authenticated-orcid":false,"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108703_bib1","doi-asserted-by":"crossref","first-page":"33847","DOI":"10.1074\/jbc.M101535200","article-title":"mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation","volume":"276","author":"Belcheva","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108703_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(91)90098-J","article-title":"ERKs: a family of protein-serine\/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF","volume":"65","author":"Boulton","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2021.108703_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0304-3959(99)00073-1","article-title":"An international survey of cancer pain characteristics and syndromes. IASP task force on cancer pain. International association for the study of pain","volume":"82","author":"Caraceni","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108703_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12035-009-8074-z","article-title":"The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence","volume":"40","author":"Chen","year":"2009","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108703_bib5","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.neuropharm.2021.108703_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.brainres.2005.11.066","article-title":"Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance","volume":"1069","author":"Cui","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108703_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102740","article-title":"Modulation of rat cancer-induced bone pain is independent of spinal microglia activity","volume":"12","author":"Diaz-delCastillo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.neuropharm.2021.108703_bib8","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1523\/JNEUROSCI.1037-07.2007","article-title":"Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury","volume":"27","author":"Erschbamer","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108703_bib9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2013.51.7219","article-title":"Pain and nociception: mechanisms of cancer-induced bone pain","volume":"32","author":"Falk","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2021.108703_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1876386300902010011","article-title":"c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury?","volume":"2","author":"Gao","year":"2009","journal-title":"Open Pain J."},{"key":"10.1016\/j.neuropharm.2021.108703_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1471-4159.2010.06946.x","article-title":"Light touch induces ERK activation in superficial dorsal horn neurons after inflammation: involvement of spinal astrocytes and JNK signaling in touch-evoked central sensitization and mechanical allodynia","volume":"115","author":"Gao","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108703_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha","volume":"110","author":"Garrett","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2021.108703_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-3959(95)00076-3","article-title":"Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service","volume":"64","author":"Grond","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108703_bib14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.neuroscience.2007.12.038","article-title":"Roles of peripheral mitogen-activated protein kinases in melittin-induced nociception and hyperalgesia","volume":"152","author":"Hao","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108703_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0165-0270(01)00420-4","article-title":"Long-term intrathecal catheterization in the rat","volume":"110","author":"Jasmin","year":"2001","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2021.108703_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1523\/JNEUROSCI.22-02-00478.2002","article-title":"ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity","volume":"22","author":"Ji","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108703_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainresrev.2008.12.011","article-title":"MAP kinase and pain","volume":"60","author":"Ji","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2021.108703_bib18","doi-asserted-by":"crossref","first-page":"15871","DOI":"10.1073\/pnas.2036503100","article-title":"Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478","volume":"100","author":"Johns","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2021.108703_bib19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1245\/s10434-006-9274-7","article-title":"STAT1 activation-induced apoptosis of esophageal squamous cell carcinoma cells in vivo","volume":"14","author":"Kaganoi","year":"2007","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.neuropharm.2021.108703_bib20","doi-asserted-by":"crossref","first-page":"h315","DOI":"10.1136\/bmj.h315","article-title":"Cancer induced bone pain","volume":"350","author":"Kane","year":"2015","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108703_bib21","first-page":"2495","article-title":"Cetuximab alleviates neuropathic pain despite tumour progression","volume":"20","author":"Kersten","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.neuropharm.2021.108703_bib22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1093\/pm\/pnz101","article-title":"Relief of neuropathic pain through epidermal growth factor receptor inhibition: a randomized proof-of-concept trial","volume":"20","author":"Kersten","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.neuropharm.2021.108703_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/bja\/aev326","article-title":"Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain","volume":"115","author":"Kersten","year":"2015","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2021.108703_bib24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/j.pain.0000000000001880","article-title":"The impact of bone cancer on the peripheral encoding of mechanical pressure stimuli","volume":"161","author":"Kucharczyk","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108703_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113286","article-title":"The stage-specific plasticity of descending modulatory controls in a rodent model of cancer-induced bone pain","volume":"12","author":"Kucharczyk","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.neuropharm.2021.108703_bib26","doi-asserted-by":"crossref","first-page":"7080s","DOI":"10.1158\/1078-0432.CCR-1004-0019","article-title":"Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.neuropharm.2021.108703_bib27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.109.152157","article-title":"Extracellular signal-regulated kinase 1\/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat","volume":"331","author":"Macey","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108703_bib28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bbrc.2006.04.186","article-title":"A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells","volume":"345","author":"Mao-Ying","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2021.108703_bib29","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1172\/JCI87406","article-title":"Epiregulin and EGFR interactions are involved in pain processing","volume":"127","author":"Martin","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2021.108703_bib30","first-page":"111","article-title":"Analgesic effect of gefitinib in the treatment of non-small cell lung cancer","volume":"4","author":"Moryl","year":"2006","journal-title":"J. Support Oncol."},{"key":"10.1016\/j.neuropharm.2021.108703_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3940(02)00141-6","article-title":"Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain","volume":"324","author":"Narita","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108703_bib32","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0460-18.2020","article-title":"EGFR signaling causes morphine tolerance and mechanical sensitization in rats","volume":"7","author":"Puig","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2021.108703_bib33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1742-2094-9-178","article-title":"Inhibition of EGFR\/MAPK signaling reduces microglial inflammatory response and the associated secondary damage in rats after spinal cord injury","volume":"9","author":"Qu","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2021.108703_bib34","doi-asserted-by":"crossref","first-page":"9980","DOI":"10.1523\/JNEUROSCI.22-22-09980.2002","article-title":"The role of spinal neuroimmune activation in morphine tolerance\/hyperalgesia in neuropathic and sham-operated rats","volume":"22","author":"Raghavendra","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108703_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.npp.1300315","article-title":"Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats","volume":"29","author":"Raghavendra","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108703_bib36","doi-asserted-by":"crossref","first-page":"a3104","DOI":"10.1136\/bmj.a3104","article-title":"Morphine remains gold standard in breakthrough cancer pain","volume":"337","author":"Ruiz-Garcia","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2021.108703_bib37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2016.00286","article-title":"The walker 256 breast cancer cell- induced bone pain model in rats","volume":"7","author":"Shenoy","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108703_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neuroscience.2012.04.065","article-title":"Extracellular signal-regulated kinase activation in spinal astrocytes and microglia contributes to cancer-induced bone pain in rats","volume":"217","author":"Wang","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108703_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1593\/neo.12328","article-title":"The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III","volume":"14","author":"Yang","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.neuropharm.2021.108703_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopha.2015.01.018","article-title":"The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma","volume":"70","author":"Yang","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2021.108703_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1756-8722-7-39","article-title":"Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells","volume":"7","author":"Yu","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.neuropharm.2021.108703_bib42","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1055\/s-0030-1271132","article-title":"Antitumor activity of taspine by modulating the EGFR signaling pathway of Erk1\/2 and Akt in vitro and in vivo","volume":"77","author":"Zhang","year":"2011","journal-title":"Planta Med."},{"key":"10.1016\/j.neuropharm.2021.108703_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pain.2004.12.022","article-title":"ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model","volume":"114","author":"Zhuang","year":"2005","journal-title":"Pain"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821002586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821002586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:15:37Z","timestamp":1758438937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821002586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"alternative-id":["S0028390821002586"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108703","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of the spinal EGFR signaling pathway in a rat model of cancer-induced bone pain with morphine tolerance","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108703"}}